BeiGene Rebuts Short-Seller Allegations, But Real Challenges May Lie Elsewhere
A report from a short-seller firm has put Beijing-based biotech bellwether BeiGene in an unwanted spotlight, prompting management to defend its record.
You may also be interested in...
Jiangsu Hengrui’s anti-PD-1 antibody is the latest to hit the immuno-oncology market in China, ensuring a fierce battle in pricing and reimbursement. Other recent new approvals include Pfizer’s antibacterial Zavicefta and a first-in-class topical treatment for psoriasis.
Junshi’s oral antiviral shows signs of effectiveness in treating patients with mild COVID-19 symptoms but more data are needed, caution researchers.
2021 saw a record number of novel drug launches and the size of the pipeline topped 20,000 candidates for the first time, new analysis shows, while China came of age as a pharma player.